All In Biotech

Drug Trial Radar · NCT03728023

A Study of AZD4205 in Healthy Adult Subjects

A Phase I, Randomized, Double Blind, Placebo Controlled 2-Parts Study to Assess the Safety, Tolerability, Pharmacokinetics of AZD4205 Following Single and Multiple Ascending Dose in Healthy Adult Subjects, and to Assess the Effect of Food on the Pharmacokinetics of AZD4205

Last checked: Nov 19, 2026Latest source record: Aug 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

66

Actual

Start

Nov 12, 2018

Primary completion

Aug 20, 2019

Study completion Aug 20, 2019

Sponsor

Lead sponsor
Dizal PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Nov 1, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is to assess the safety, tolerability, pharmacokinetics of AZD4205 following single and multiple ascending dose in healthy adult subjects, and to assess the effect of food on the pharmacokinetics of AZD4205.

Conditions

  • Healthy Volunteers

Interventions

  • AZD4205Drug

    SAD: 5mg, 20mg, 50mg, 100mg and 150mg MAD: low, medium and high dose once daily X14 days

  • PlaceboDrug

    Single dose in SAD and once daily for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of subjects with adverse eventsTime frame: From screening up to 28 days after last dose (day29 for MAD, day 43 for food effect, day 42 for MAD)
  2. The number of subjects with abnormal laboratory parametersTime frame: From screening up to 28 days after last dose (day29 for MAD, day 43 for food effect, day 42 for MAD)
  3. The number of subjects with abnormal vital signsTime frame: From screening up to 28 days after last dose (day29 for MAD, day 43 for food effect, day 42 for MAD)
  4. The number of subjects with abnormal electrocardiogramTime frame: From screening up to 28 days after last dose (day29 for MAD, day 43 for food effect, day 42 for MAD)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Frontage clinical service

    Secaucus, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.